Jammu And Kashmir Headlines

Chronic Pain Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials | Key Companies – Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Medtronic Plc.

 Breaking News
  • No posts were found

Chronic Pain Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials | Key Companies – Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Medtronic Plc.

May 23
23:50 2023
Chronic Pain Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials | Key Companies - Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Medtronic Plc.
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Pain pipeline constitutes key companies continuously working towards developing Chronic Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Chronic Pain Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Pain Market.

 

The Chronic Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Chronic Pain Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Pain treatment therapies with a considerable amount of success over the years. 
  • Chronic Pain companies working in the treatment market are Ribomic, BRIM Biotechnology, Oryn Therapeutics, GlaxoSmithKline, Peptinov, Kangstem Biotech, Celltex Therapeutics, Wuhan Createrna Science and Technology, Synact Pharma, OliPass Corporation, Selecta Bioscience, Mabion SA, Biosplice Therapeutics, and others, are developing therapies for the Chronic Pain treatment 
  • Emerging Chronic Pain therapies such as – RBM-010, BRM521, ORTD 1, GSK 3858279, PPV 06, FURESTEM-RA, Autologous Adiposederived Stem Cells, QR 052, AP1189, OLP 1002, SEL 212, MabionCD20, Lorecivivint, and others are expected to have a significant impact on the Chronic Pain market in the coming years.   
  • In September 2022, A double-blind, multi-center, randomised, placebo-controlled study of the safety and efficacy of 12 weeks of extended treatment with AP1189 in early RA patients new to DMARD treatment was started by SynAct Pharma
  • In September 2021, The licencing agreement between Biosplice Therapeutics and Haisco Pharmaceutical Group Co., Ltd. was recently signed, and it gives Haisco the exclusive right to produce and market lorecivivint (SM04690) in China for the treatment of knee osteoarthritis (“OA”) and other musculoskeletal diseases

 

Chronic Pain Overview

Chronic pain is persistent pain that lasts longer than the typical healing time or coexists with a chronic health condition, like arthritis. The duration of chronic discomfort is greater. It could be continuous or sporadic. For instance, even if a headache isn’t always present, it might be deemed chronic pain when it lasts for several months or years.

 

Get a Free Sample PDF Report to know more about Chronic Pain Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/chronic-pain-pipeline-insight

 

Emerging Chronic Pain Drugs Under Different Phases of Clinical Development Include:

  • RBM-010: Ribomic
  • BRM521: BRIM Biotechnology
  • ORTD 1: Oryn Therapeutics
  • GSK 3858279: GlaxoSmithKline
  • PPV 06: Peptinov
  • FURESTEM-RA: Kangstem Biotech
  • Autologous Adiposederived Stem Cells: Celltex Therapeutics
  • QR 052: Wuhan Createrna Science and Technology
  • AP1189: Synact Pharma
  • OLP 1002: OliPass Corporation
  • SEL 212: Selecta Bioscience
  • MabionCD20: Mabion SA
  • Lorecivivint: Biosplice Therapeutics

 

Chronic Pain Pipeline Therapeutics Assessment

  • Chronic Pain Assessment by Product Type
  • Chronic Pain By Stage and Product Type
  • Chronic Pain Assessment by Route of Administration
  • Chronic Pain By Stage and Route of Administration
  • Chronic Pain Assessment by Molecule Type
  • Chronic Pain by Stage and Molecule Type

 

DelveInsight’s Chronic Pain Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Chronic Pain product details are provided in the report. Download the Chronic Pain pipeline report to learn more about the emerging Chronic Pain therapies

 

Some of the key companies in the Chronic Pain Therapeutics Market include:

Key companies developing therapies for Chronic Pain are – Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Medtronic Plc., Boston Scientific Corporation, Novartis AG, Johnson & Johnson, AstraZeneca PLC, Bristol-Myers Squibb Company, Becton and among others.

 

Chronic Pain Pipeline Analysis:

The Chronic Pain pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Pain with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Pain Treatment.
  • Chronic Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Pain market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Pain drugs and therapies

 

Chronic Pain Pipeline Market Drivers

  • Increasing prevalence of various types of chronic pain, such as lower back pain, severe headache or migraine pain, and facial pain, growing geriatric population across the world are some of the important factors that are fueling the Chronic Pain Market.

 

Chronic Pain Pipeline Market Barriers

  • However, addiction and toxicity associated with the drugs, high cost associated with the treatment and other factors are creating obstacles in the Chronic Pain Market growth.

 

Scope of Chronic Pain Pipeline Drug Insight    

  • Coverage: Global
  • Key Chronic Pain Companies: Ribomic, BRIM Biotechnology, Oryn Therapeutics, GlaxoSmithKline, Peptinov, Kangstem Biotech, Celltex Therapeutics, Wuhan Createrna Science and Technology, Synact Pharma, OliPass Corporation, Selecta Bioscience, Mabion SA, Biosplice Therapeutics, and others
  • Key Chronic Pain Therapies: RBM-010, BRM521, ORTD 1, GSK 3858279, PPV 06, FURESTEM-RA, Autologous Adiposederived Stem Cells, QR 052, AP1189, OLP 1002, SEL 212, MabionCD20, Lorecivivint, and others
  • Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
  • Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers 

 

Request for Sample PDF Report for Chronic Pain Pipeline Assessment and clinical trials

 

Table of Contents

1

Chronic Pain Report Introduction

2

Chronic Pain Executive Summary

3

Chronic Pain Overview

4

Chronic Pain- Analytical Perspective In-depth Commercial Assessment

5

Chronic Pain Pipeline Therapeutics

6

Chronic Pain Late Stage Products (Phase II/III)

7

Chronic Pain Mid Stage Products (Phase II)

8

Chronic Pain Early Stage Products (Phase I)

9

Chronic Pain Preclinical Stage Products

10

Chronic Pain Therapeutics Assessment

11

Chronic Pain Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Chronic Pain Key Companies

14

Chronic Pain Key Products

15

Chronic Pain Unmet Needs

16 

Chronic Pain Market Drivers and Barriers

17

Chronic Pain Future Perspectives and Conclusion

18

Chronic Pain Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services